446 related articles for article (PubMed ID: 15665253)
1. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
2. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
[TBL] [Abstract][Full Text] [Related]
3. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.
Pennington MW; Beeton C; Galea CA; Smith BJ; Chi V; Monaghan KP; Garcia A; Rangaraju S; Giuffrida A; Plank D; Crossley G; Nugent D; Khaytin I; Lefievre Y; Peshenko I; Dixon C; Chauhan S; Orzel A; Inoue T; Hu X; Moore RV; Norton RS; Chandy KG
Mol Pharmacol; 2009 Apr; 75(4):762-73. PubMed ID: 19122005
[TBL] [Abstract][Full Text] [Related]
4. Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.
Beeton C; Wulff H; Barbaria J; Clot-Faybesse O; Pennington M; Bernard D; Cahalan MD; Chandy KG; Béraud E
Proc Natl Acad Sci U S A; 2001 Nov; 98(24):13942-7. PubMed ID: 11717451
[TBL] [Abstract][Full Text] [Related]
5. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.
Beeton C; Barbaria J; Giraud P; Devaux J; Benoliel AM; Gola M; Sabatier JM; Bernard D; Crest M; Béraud E
J Immunol; 2001 Jan; 166(2):936-44. PubMed ID: 11145670
[TBL] [Abstract][Full Text] [Related]
6. Analogs of the sea anemone potassium channel blocker ShK for the treatment of autoimmune diseases.
Beeton C; Pennington MW; Norton RS
Inflamm Allergy Drug Targets; 2011 Oct; 10(5):313-21. PubMed ID: 21824083
[TBL] [Abstract][Full Text] [Related]
7. Kv1.3 channel-blocking immunomodulatory peptides from parasitic worms: implications for autoimmune diseases.
Chhabra S; Chang SC; Nguyen HM; Huq R; Tanner MR; Londono LM; Estrada R; Dhawan V; Chauhan S; Upadhyay SK; Gindin M; Hotez PJ; Valenzuela JG; Mohanty B; Swarbrick JD; Wulff H; Iadonato SP; Gutman GA; Beeton C; Pennington MW; Norton RS; Chandy KG
FASEB J; 2014 Sep; 28(9):3952-64. PubMed ID: 24891519
[TBL] [Abstract][Full Text] [Related]
8. Imaging of effector memory T cells during a delayed-type hypersensitivity reaction and suppression by Kv1.3 channel block.
Matheu MP; Beeton C; Garcia A; Chi V; Rangaraju S; Safrina O; Monaghan K; Uemura MI; Li D; Pal S; de la Maza LM; Monuki E; Flügel A; Pennington MW; Parker I; Chandy KG; Cahalan MD
Immunity; 2008 Oct; 29(4):602-14. PubMed ID: 18835197
[TBL] [Abstract][Full Text] [Related]
9. N-Terminally extended analogues of the K⁺ channel toxin from Stichodactyla helianthus as potent and selective blockers of the voltage-gated potassium channel Kv1.3.
Chang SC; Huq R; Chhabra S; Beeton C; Pennington MW; Smith BJ; Norton RS
FEBS J; 2015 Jun; 282(12):2247-59. PubMed ID: 25864722
[TBL] [Abstract][Full Text] [Related]
10. The D-diastereomer of ShK toxin selectively blocks voltage-gated K+ channels and inhibits T lymphocyte proliferation.
Beeton C; Smith BJ; Sabo JK; Crossley G; Nugent D; Khaytin I; Chi V; Chandy KG; Pennington MW; Norton RS
J Biol Chem; 2008 Jan; 283(2):988-97. PubMed ID: 17984097
[TBL] [Abstract][Full Text] [Related]
11. Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases.
Norton RS; Pennington MW; Wulff H
Curr Med Chem; 2004 Dec; 11(23):3041-52. PubMed ID: 15578998
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive evidence of Tityus serrulatus toxins Ts6 and Ts15: insights of a novel K(+) channel pattern in T cells.
Pucca MB; Bertolini TB; Cerni FA; Bordon KC; Peigneur S; Tytgat J; Bonato VL; Arantes EC
Immunology; 2016 Feb; 147(2):240-50. PubMed ID: 26595158
[TBL] [Abstract][Full Text] [Related]
13. Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Tarcha EJ; Chi V; Muñoz-Elías EJ; Bailey D; Londono LM; Upadhyay SK; Norton K; Banks A; Tjong I; Nguyen H; Hu X; Ruppert GW; Boley SE; Slauter R; Sams J; Knapp B; Kentala D; Hansen Z; Pennington MW; Beeton C; Chandy KG; Iadonato SP
J Pharmacol Exp Ther; 2012 Sep; 342(3):642-53. PubMed ID: 22637724
[TBL] [Abstract][Full Text] [Related]
14. Blocking KV1.3 channels inhibits Th2 lymphocyte function and treats a rat model of asthma.
Koshy S; Huq R; Tanner MR; Atik MA; Porter PC; Khan FS; Pennington MW; Hanania NA; Corry DB; Beeton C
J Biol Chem; 2014 May; 289(18):12623-32. PubMed ID: 24644290
[TBL] [Abstract][Full Text] [Related]
15. The voltage-gated Kv1.3 K(+) channel in effector memory T cells as new target for MS.
Wulff H; Calabresi PA; Allie R; Yun S; Pennington M; Beeton C; Chandy KG
J Clin Invest; 2003 Jun; 111(11):1703-13. PubMed ID: 12782673
[TBL] [Abstract][Full Text] [Related]
16. ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide.
Kalman K; Pennington MW; Lanigan MD; Nguyen A; Rauer H; Mahnir V; Paschetto K; Kem WR; Grissmer S; Gutman GA; Christian EP; Cahalan MD; Norton RS; Chandy KG
J Biol Chem; 1998 Dec; 273(49):32697-707. PubMed ID: 9830012
[TBL] [Abstract][Full Text] [Related]
17. Development of highly selective Kv1.3-blocking peptides based on the sea anemone peptide ShK.
Pennington MW; Chang SC; Chauhan S; Huq R; Tajhya RB; Chhabra S; Norton RS; Beeton C
Mar Drugs; 2015 Jan; 13(1):529-42. PubMed ID: 25603346
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the functional properties of the voltage-gated potassium channel Kv1.3 in human CD4+ T lymphocytes.
Hu L; Pennington M; Jiang Q; Whartenby KA; Calabresi PA
J Immunol; 2007 Oct; 179(7):4563-70. PubMed ID: 17878353
[TBL] [Abstract][Full Text] [Related]
19. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
[TBL] [Abstract][Full Text] [Related]
20. A novel fluorescent toxin to detect and investigate Kv1.3 channel up-regulation in chronically activated T lymphocytes.
Beeton C; Wulff H; Singh S; Botsko S; Crossley G; Gutman GA; Cahalan MD; Pennington M; Chandy KG
J Biol Chem; 2003 Mar; 278(11):9928-37. PubMed ID: 12511563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]